A Multiple Ascending Dose Study of KBP-7072 in Healthy Subjects

Phase 1 Completed 16 enrolled KBP Biosciences

RandomizedParallel-groupSingle-blindTreatment

Summary

This is a randomized, single-blind, placebo-controlled, sequential parallel-group and multiple ascending dose (MAD) study to evaluate the safety, tolerability and pharmacokinetics of KBP 7072 in healthy subjects. The safety will be assessed at each dose level before progressing to the next higher dose.

Timeline

Start: 2015-10
Primary completion: 2015-12
Completion: 2015-12

Publications

Huband MD, Mendes RE, Pfaller MA, Lindley JM, Strand GJ, Benn VJ, Zhang J, Li L, Zhang M, Tan X, Liu Q, Flamm RK. In Vitro Activity of KBP-7072, a Novel Third-Generation Tetracycline, against 531 Recent Geographically Diverse and Molecularly Characterized Acinetobacter baumannii Species Complex Isolates. Antimicrob Agents Chemother. 2020 Apr 21;64(5):e02375-19. doi: 10.1128/AAC.02375-19. Print 2020 Apr 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	KBP-7072	Small molecule	—	—

Indications

No indication recorded.